BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
274.73
-0.55 (-0.20%)
Mar 23, 2026, 4:00 PM EDT - Market closed
BeOne Medicines AG Revenue
In the year 2025, BeOne Medicines AG had annual revenue of $5.34B with 40.23% growth. BeOne Medicines AG had revenue of $1.50B in the quarter ending December 31, 2025, with 32.84% growth.
Revenue (ttm)
$5.34B
Revenue Growth
+40.23%
P/S Ratio
5.70
Revenue / Employee
$445,253
Employees
12,000
Market Cap
30.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.34B | 1.53B | 40.23% |
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | 198.22M | -40.17M | -16.85% |
| Dec 31, 2017 | 238.39M | 237.32M | 22,179.16% |
| Dec 31, 2016 | 1.07M | -7.75M | -87.86% |
| Dec 31, 2015 | 8.82M | -4.22M | -32.37% |
| Dec 31, 2014 | 13.04M | 1.89M | 16.93% |
| Dec 31, 2013 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Incyte | 5.14B |
| argenx SE | 4.24B |
| Genmab | 3.72B |
| Alnylam Pharmaceuticals | 3.71B |
| BioNTech SE | 3.37B |
| Royalty Pharma | 2.38B |
| Moderna | 1.94B |
| Insmed | 606.42M |
ONC News
- 7 days ago - ONC: Jefferies Downgrades BeOne Medicines to Hold, Lowers Price Target | ONC Stock News - GuruFocus
- 20 days ago - BeOne Medicines Ltd (ONC) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion - GuruFocus
- 20 days ago - Q4 2025 BeOne Medicines AG Earnings Call Transcript - GuruFocus
- 20 days ago - BeOne Medicines is Now Oversold (ONC) - Nasdaq
- 21 days ago - BeOne Medicines AG at TD Cowen Healthcare Conference Transcript - GuruFocus
- 21 days ago - BeOne Medicines (ONC) Shares Cross Below 200 DMA - Nasdaq
- 24 days ago - BeOne Medicines (ONC) Rating Maintained, Price Target Raised by RBC Capital | ONC Stock News - GuruFocus
- 24 days ago - ONC: Guggenheim Elevates Price Target for BeOne Medicines | ONC Stock News - GuruFocus